Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TevaGastrim for Stem Cell Mobilization in Sibling Donors
NCT01542944Phase 2Completed
- Sponsor
- Sheba Medical Center
- Start
- Feb 2012
- Primary completion
- Apr 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tbo-filgrastim in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Sheba Medical Center. Primary endpoint: Mobilisation success rate at 4 weeks. Started Feb 2012; status: completed.
02
Drugs
tbo-filgrastim
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01542944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01542944.